Special Issue

Epidemiological, Basic Science and Clinical Research Studies in Heart Failure

Message from the Guest Editor

This Special Issue will expand the published evidence on heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and advanced heart failure by calling for epidemiological, basic science, and clinical research studies that will evaluate the following:

- 1. The pathophysiological mechanisms that lead to heart failure, including the impact of racial/ethnic and gender differences;
- Traditional and emerging risk factors for heart failure and how they can be modified to reduce future heart failure risk through pharmacologic and nonpharmacologic interventions;
- 3. Diverse types of cardiomyopathies that can result in heart failure, including, but not limited to, cardiac amyloidosis, hypertrophic cardiomyopathy, and sarcoidosis:
- 4. The impact of social determinants of health on heart failure outcomes;
- 5. Implementation science studies on the real-life effectiveness of heart failure interventions.

Guest Editor

Dr. Imo A. Ebong

Division of Cardiology, University of California-Davis, Sacramento, CA 95817, USA

Deadline for manuscript submissions

31 October 2025



Journal of
Cardiovascular
Development and
Disease

an Open Access Journal by MDPI

Impact Factor 2.3 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/222939

Journal of Cardiovascular Development and Disease Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcdd@mdpi.com

mdpi.com/journal/ jcdd





Journal of Cardiovascular Development and Disease

an Open Access Journal by MDPI

Impact Factor 2.3 CiteScore 3.7 Indexed in PubMed





Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (*JCDD*, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand

National Heart & Lung Institute, Imperial College London, South Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) / CiteScore - Q2 (General Pharmacology, Toxicology and Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

